It is still unknown if serum glial fibrillary acidic protein (GFAP) is a useful marker in frontotemporal lobar degeneration (FTLD).
Objective:
To assess the diagnostic and prognostic value of serum GFAP in a large cohort of patients with FTLD.
Methods:
In this retrospective study, performed on 406 participants, we measured serum GFAP concentration with an ultrasensitive Single molecule array (Simoa) method in patients with FTLD, Alzheimer’s disease (AD), and in cognitively unimpaired elderly controls. We assessed the role of GFAP as marker of disease severity by analyzing the correlation with clinical variables, neurophysiological data, and cross-sectional brain imaging. Moreover, we evaluated the role of serum GFAP as a prognostic marker of disease survival.
Results:
We observed significantly higher levels of serum GFAP in patients with FTLD syndromes, except progressive supranuclear palsy, compared with healthy controls, but not compared with AD patients. In FTLD, serum GFAP levels correlated with measures of cognitive dysfunction and disease severity, and were associated with indirect measures of GABAergic deficit. Serum GFAP concentration was not a significant predictor of survival.
Conclusion:
Serum GFAP is increased in FTLD, correlates with cognition and GABAergic deficits, and thus shows promise as a biomarker of disease severity in FTLD.
Baizabal-CarvalloJF, JankovicJ (2016) Parkinsonism, movement disorders and genetics in frontotemporal dementia, Nat Rev Neurol12, 175–185.
3.
Lomen-HoerthC, AndersonT, MillerB (2002) The overlap of amyotrophic lateral sclerosis and frontotemporal dementia, Neurology59, 1077–1079.
4.
CairnsNJ, BigioEH, MackenzieIRA, NeumannM, LeeVMY, HatanpaaKJ, WhiteIII CL, SchneiderJA, HallidayG, DuyckaertsC, HolmIE, OkamotoK, MunozDG, DicksonDW, IncePG, TrojanowskiJQ, MannDMA (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: Consensus of the Consortium for Frontotemporal Lobar Degeneration, Acta Neuropathol114, 5–22.
5.
MackenzieIRA, BaborieA, Pickering-BrownS, PlessisD Du, JarosE, PerryRH, NearyD, SnowdenJS, MannDMA (2006) Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: Classification and relation to clinical phenotype, Acta Neuropathol112, 539–549.
6.
MeeterLH, KaatLD, RohrerJD, van SwietenJC (2017) Imaging and fluid biomarkers in frontotemporal dementia, Nat Rev Neurol19, 109.
7.
BorroniB, BenussiA, PremiE, AlbericiA, MarcelloE, GardoniF, Di LucaM, PadovaniA (2018) Biological, neuroimaging, and neurophysiological markers in frontotemporal dementia: Three faces of the same coin, J Alzheimers Dis62, 1113–1123.
8.
BenussiA, GrassiM, PalluzziF, KochG, Di LazzaroV, NardoneR, CantoniV, Dell’EraV, PremiE, MartoranaA, di LorenzoF, BonnìS, RanieriF, CaponeF, MusumeciG, CotelliMS, PadovaniA, BorroniB (2020) Classification accuracy of transcranial magnetic stimulation for the diagnosis of neurodegenerative dementias, Ann Neurol87, 394–404.
9.
FoianiMS, WoollacottIOC, HellerC, BocchettaM, HeslegraveA, DickKM, RussellLL, MarshallCR, MeadS, SchottJM, FoxNC, WarrenJD, ZetterbergH, RohrerJD (2018) Plasma tau is increased in frontotemporal dementia, J Neurol Neurosurg Psychiatry89, 804–807.
10.
RohrerJD, WoollacottIOC, DickKM, BrotherhoodE, GordonE, FellowsA, ToombsJ, DruyehR, CardosoMJ, OurselinS, NicholasJM, NorgrenN, MeadS, AndreassonU, BlennowK, SchottJM, FoxNC, WarrenJD, ZetterbergH (2016) Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia, Neurology87, 1329–1336.
11.
MeeterLH, DopperEG, JiskootLC, Sanchez-ValleR, GraffC, BenussiL, GhidoniR, PijnenburgYA, BorroniB, GalimbertiD, LaforceRJ, MasellisM, VandenbergheR, Ber ILe, OttoM, van MinkelenR, PapmaJM, RomboutsSA, BalasaM, ÖijerstedtL, JelicV, DickKM, CashDM, HardingSR, Jorge CardosoM, OurselinS, RossorMN, PadovaniA, ScarpiniE, FenoglioC, TartagliaMC, LamariF, BarroC, KuhleJ, RohrerJD, TeunissenCE, van SwietenJC (2016) Neurofilament light chain: A biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol3, 623–636.
12.
KarikariTK, PascoalTA, AshtonNJ, JanelidzeS, BenedetAL, RodriguezJL, ChamounM, SavardM, KangMS, TherriaultJ, SchöllM, MassarwehG, SoucyJ-P, HöglundK, BrinkmalmG, MattssonN, PalmqvistS, GauthierS, StomrudE, ZetterbergH, HanssonO, Rosa-NetoP, BlennowK (2020) Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts, Lancet Neurol19, 422–433.
13.
ThijssenEH, La JoieR, WolfA, StromA, WangP, IaccarinoL, BourakovaV, CobigoY, HeuerH, SpinaS, VandeVredeL, ChaiX, ProctorNK, AireyDC, ShcherbininS, Duggan EvansC, SimsJR, ZetterbergH, BlennowK, KarydasAM, TeunissenCE, KramerJH, GrinbergLT, SeeleyWW, RosenH, BoeveBF, MillerBL, RabinoviciGD, DageJL, RojasJC, BoxerAL, Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators (2020) Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration, Nat Med26, 387–397.
14.
BenussiA, KarikariT, AshtonN, GazzinaS, PremiE, BenussiL, GhidoniR, RodriguezJL, EmeršičA, SimrénJ, BinettiB, FostinelliS, GiuntaM, GasparottiR, ZetterbergH, BlennowK, BorroniB (2020) Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry91, 960–967.
OecklP, WeydtP, SteinackerP, Anderl-StraubS, NordinF, VolkAE, Diehl-SchmidJ, AndersenPM, KornhuberJ, DanekA, FassbenderK, FliessbachK, JahnH, LauerM, MüllerK, KnehrA, PrudloJ, SchneiderA, ThalDR, Yilmazer-HankeD, WeishauptJH, LudolphAC, OttoM (2019) Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase, J Neurol Neurosurg Psychiatry90, 4–10.
17.
IshikiA, KamadaM, KawamuraY, TeraoC, ShimodaF, TomitaN, AraiH, FurukawaK (2016) Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration, J Neurochem136, 258–261.
18.
OecklP, HalbgebauerS, Anderl-StraubS, SteinackerP, HussaAM, NeugebauerH, Von ArnimCAF, Diehl-SchmidJ, GrimmerT, KornhuberJ, LewczukP, DanekA, DegenerationL, LudolphAC, OttoM (2019) Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment, J Alzheimers Dis67, 481–488.
19.
Abu-RumeilehS, SteinackerP, PolischiB, MammanaA, Bartoletti-StellaA, OecklP, BaiardiS, ZenesiniC, HussA, CortelliP, CapellariS, OttoM, ParchiP (2019) CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia, Alzheimers Res Ther12, 1–15.
ArmstrongMJ, LitvanI, LangAE, BakTH, BhatiaKP, BorroniB, BoxerAL, DicksonDW, GrossmanM, HallettM, JosephsKA, KerteszA, LeeSE, MillerBL, ReichSG, RileyDE, TolosaE, TrösterAI, VidailhetM, WeinerWJ (2013) Criteria for the diagnosis of corticobasal degeneration, Neurology80, 496–503.
24.
LitvanI, AgidY, CalneD, CampbellG, DuboisB, DuvoisinRC, GoetzCG, GolbeLI, GrafmanJ, GrowdonJH, HallettM, JankovicJ, QuinnNP, TolosaE, ZeeDS (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop, Neurology47, 1–9.
25.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement7, 270–279.
26.
BorroniB, BenussiA, CossedduM, ArchettiS, PadovaniA (2014) Cerebrospinal fluid tau levels predict prognosis in non-inherited frontotemporal dementia, Neurodegener Dis13, 224–229.
27.
FostinelliS, CianiM, ZanardiniR, ZanettiO, BinettiG, GhidoniR, BenussiL (2018) The heritability of frontotemporal lobar degeneration: Validation of pedigree classification criteria in a Northern Italy cohort, J Alzheimers Dis61, 753–760.
RossiniPM, BurkeD, ChenR, CohenLG, DaskalakisZ, Di IorioR, Di LazzaroV, FerreriF, FitzgeraldPB, GeorgeMS, HallettM, LefaucheurJP, LangguthB, MatsumotoH, MiniussiC, NitscheMA, Pascual-LeoneA, PaulusW, RossiS, RothwellJC, SiebnerHR, UgawaY, WalshV, ZiemannU (2015) Non-invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves: Basic principles and procedures for routine clinical and research application. An updated report from an I.F.C.N. Committee, Clin Neurophysiol126, 1071–1107.
30.
Di LazzaroV, OlivieroA, ProficeP, PennisiMA, Di GiovanniS, ZitoG, TonaliP, RothwellJC (2000) Muscarinic receptor blockade has differential effects on the excitability of intracortical circuits in the human motor cortex, Exp Brain Res135, 455–461.
31.
MagniE, BinettiG, BianchettiA, RozziniR, TrabucchiM (1996) Mini-Mental State Examination: A normative study in Italian elderly population, Eur J Neurol3, 198–202.
32.
NovelliG, PapagnoC, CapitaniE, LaiaconaM (1970) Tre test clinici di memoria verbale a lungo termine: Taratura su soggetti normali. / Three clinical tests for the assessment, Arch Psicol Neurol Psichiatr47, 278–296.
33.
CaffarraP, VezzadiniG, DieciF, ZonatoF, VenneriA (2002) Rey-Osterrieth complex figure: Normative values in an Italian population sample, Neurol Sci22, 443–447.
34.
NovelliG, PapagnoC, CapitaniE, LaiaconaM, VallarG, CappaSF (1986) Tre test clinici di ricerca e produzione lessicale. Taratura su sogetti normali, Arch Psicol Neurol Psichiatr47, 477–506.
35.
De RenziE, VignoloLA (1962) The token test: A sensitive test to detect receptive disturbances in aphasics, Brain85, 665–678.
36.
SunderlandT, HillJL, MellowAM, LawlorBA, GundersheimerJ, NewhousePA, GrafmanJH (1989) Clock drawing in Alzheimer’s disease. A novel measure of dementia severity, J Am Geriatr Soc37, 725–729.
37.
GiovagnoliAR, Del PesceM, MascheroniS, SimoncelliM, LaiaconaM, CapitaniE (1996) Trail making test: Normative values from 287 normal adult controls, Ital J Neurol Sci17, 305–309.
38.
KnopmanDS, KramerJH, BoeveBF, CaselliRJ, Graff-RadfordNR, MendezMF, MillerBL, MercaldoN (2008) Development of methodology for conducting clinical trials in frontotemporal lobar degeneration, Brain131, 2957–2968.
39.
KatzS, FordAB, MoskowitzRW, JacksonBA, JaffeMW (1963) Studies of illness in the aged. The Index of ADL: A standardized measure of biological and psychosocial function, JAMA185, 914–919.
40.
LawtonMP, BrodyEM (1969) Assessment of older people: Self-maintaining and instrumental activities of daily living, Gerontologist9, 179–186.
KujiraiT, CaramiaMD, RothwellJC, DayBL, ThompsonPD, FerbertA, WroeS, AsselmanP, MarsdenCD (1993) Corticocortical inhibition in human motor cortex, J Physiol471, 501–519.
48.
ZiemannU, RothwellJC, RiddingMC (1996) Interaction between intracortical inhibition and facilitation in human motor cortex, J Physiol496, 873–881.
49.
Valls-SoléJ, Pascual-LeoneA, WassermannEM, HallettM (1992) Human motor evoked responses to paired transcranial magnetic stimuli, Electroencephalogr Clin Neurophysiol85, 355–364.
50.
TokimuraH, Di LazzaroV, TokimuraY, OlivieroA, ProficeP, InsolaA, MazzoneP, TonaliP, RothwellJC (2000) Short latency inhibition of human hand motor cortex by somatosensory input from the hand, J Physiol523(Pt 2), 503–513.
51.
MarelliC, HourregueC, GutierrezL-A, PaquetC, Menjot de ChampfleurN, De VerbizierD, JacobM, DuboisJ, MaleskaAM, HirtzC, NavucetS, BennysK, DumurgierJ, CognatE, BerrC, MagninE, LehmannS, GabelleA (2020) Cerebrospinal fluid and plasma biomarkers do not differ in the presenile and late-onset behavioral variants of frontotemporal dementia, J Alzheimers Dis74, 903–911.
52.
HolmbergB, RosengrenL, KarlssonJE, JohnelsB (1998) Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson’s disease, Mov Disord13, 70–77.
53.
ConstantinescuR, RosengrenL, JohnelsB, ZetterbergH, HolmbergB (2010) Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson’s disease and atypical parkinsonian disorders, Parkinsonism Relat Disord16, 142–145.
54.
ConstantinescuR, ZetterbergH, HolmbergB, RosengrenL (2009) Levels of brain related proteins in cerebrospinal fluid: An aid in the differential diagnosis of parkinsonian disorders, Parkinsonism Relat Disord15, 205–212.
55.
SüssmuthSD, UttnerI, LandwehrmeyerB, PinkhardtEH, BrettschneiderJ, PetzoldA, KramerB, SchulzJB, PalmC, OttoM, LudolphAC, KassubekJ, TumaniH (2010) Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes, Mov Disord25, 1284–1288.
56.
AriasC, ZepedaA, Hernández-OrtegaK, Leal-GaliciaP, LojeroC, Camacho-ArroyoI (2009) Sex and estrous cycle-dependent differences in glial fibrillary acidic protein immunoreactivity in the adult rat hippocampus, Horm Behav55, 257–263.
57.
HutchinsonAD, MathiasJL (2007) Neuropsychological deficits in frontotemporal dementia and Alzheimer’s disease: A meta-analytic review, J Neurol Neurosurg Psychiatry78, 917–928.
58.
HodgesJR, PattersonK, WardR, GarrardP, BakT, PerryR, GregoryC (1999) The differentiation of semantic dementia and frontal lobe dementia (temporal and frontal variants of frontotemporal dementia) from early Alzheimer’s disease: A comparative neuropsychological study, Neuropsychology13, 31–40.
59.
PadovaniA, BenussiA, CantoniV, Dell’EraV, CotelliMS, CaratozzoloS, TurroneR, RozziniL, AlbericiA, AltomareD, DepariA, FlamminiA, FrisoniGB, BorroniB (2018) Diagnosis of mild cognitive impairment due to Alzheimer’s disease with transcranial magnetic stimulation, J Alzheimers Dis65, 221–230.
60.
BenussiA, AlbericiA, BurattiE, GhidoniR, GardoniF, Di LucaM, PadovaniA, BorroniB (2019) Toward a glutamate hypothesis of frontotemporal dementia, Front Neurosci13, 304.
61.
BenussiA, Dell’EraV, CantoniV, FerrariC, CaratozzoloS, RozziniL, AlbericiA, PadovaniA, BorroniB (2018) Discrimination of atypical parkinsonisms with transcranial magnetic stimulation, Brain Stimul11, 366–373.
62.
PadovaniA, BenussiA, CotelliMS, FerrariC, CantoniV, Dell’EraV, TurroneR, PagheraB, BorroniB (2019) Transcranial magnetic stimulation and amyloid markers in mild cognitive impairment: Impact on diagnostic confidence and diagnostic accuracy, Alzheimers Res Ther11, 95.
63.
BenussiA, AlbericiA, FerrariC, CantoniV, Dell’EraV, TurroneR, CotelliMS, BinettiG, PagheraB, KochG, PadovaniA, BorroniB (2018) The impact of transcranial magnetic stimulation on diagnostic confidence in patients with Alzheimer disease, Alzheimers Res Ther10, 94.
64.
GazzinaS, BenussiA, PremiE, PaternicòD, CristilloV, Dell’EraV, CossedduM, ArchettiS, AlbericiA, GasparottiR, PadovaniA, BorroniB (2018) Neuroanatomical correlates of transcranial magnetic stimulation in presymptomatic granulin mutation carriers, Brain Topogr31, 488–497.
65.
BenussiA, Dell’EraV, CantoniV, CotelliMS, CossedduM, SpallazziM, MicheliA, TurroneR, AlbericiA, BorroniB (2020) TMS for staging and predicting functional decline in frontotemporal dementia, Brain Stimul13, 386–392.
66.
BenussiA, Dell’EraV, CantoniV, CotelliMS, CossedduM, SpallazziM, AlbericiA, PadovaniA, BorroniB (2020) Neurophysiological correlates of positive and negative symptoms in frontotemporal dementia, J Alzheimers Dis73, 1133–1142.
67.
MederosS, PereaG (2019) GABAergic-astrocyte signaling: A refinement of inhibitory brain networks, Glia67, 1842–1851.
68.
RobelS, SontheimerH (2016) Glia as drivers of abnormal neuronal activity, Nat Neurosci19, 28–33.
69.
MottaC, Di LorenzoF, PonzoV, PellicciariMC, BonnìS, PicazioS, MercuriNB, CaltagironeC, MartoranaA, KochG (2018) Transcranial magnetic stimulation predicts cognitive decline in patients with Alzheimer’s disease, J Neurol Neurosurg Psychiatry89, 1237–1242.
70.
Di LazzaroV (2018) Emergence of neurophysiological biomarkers of Alzheimer disease, J Neurol Neurosurg Psychiatry89, 1235.
71.
DvorakF, HabererI, SitzerM, FoerchC (2009) Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke, Cerebrovasc Dis27, 37–41.
72.
PapaL, SilvestriS, BrophyGM, GiordanoP, FalkJL, BragaCF, TanCN, AmeliNJ, DemeryJA, DixitNK, MendesME, HayesRL, WangKKW, RobertsonCS (2014) GFAP out-performs S100β in detecting traumatic intracranial lesions on computed tomography in trauma patients with mild traumatic brain injury and those with extracranial lesions, J Neurotrauma31, 1815–1822.
73.
OlssonB, LautnerR, AndreassonU, ÖhrfeltA, PorteliusE, BjerkeM, HölttäM, RosénC, OlssonC, StrobelG, WuE, DakinK, PetzoldM, BlennowK, ZetterbergH (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis, Lancet Neurol15, 673–684.
74.
VågbergM, NorgrenN, DringA, LindqvistT, BirganderR, ZetterbergH, SvenningssonA (2015) Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction, PLoS One10, 1–8.
75.
Young-BernierM, TanguayAN, DavidsonPSR, TremblayF (2014) Short-latency afferent inhibition is a poor predictor of individual susceptibility to rTMS-induced plasticity in the motor cortex of young and older adults, Front Aging Neurosci6, 182.
76.
Di LorenzoF, PonzoV, BonnìS, MottaC, Negrão SerraPC, BozzaliM, CaltagironeC, MartoranaA, KochG (2016) Long-term potentiation-like cortical plasticity is disrupted in Alzheimer’s disease patients independently from age of onset, Ann Neurol80, 202–210.
77.
Di LazzaroV, PilatoF, DileoneM, TonaliPA, ZiemannU (2005) Dissociated effects of diazepam and lorazepam on short-latency afferent inhibition, J Physiol569, 315–23.
78.
Di LazzaroV, OlivieroA, SaturnoE, DileoneM, PilatoF, NardoneR, RanieriF, MusumeciG, FiorillaT, TonaliP (2005) Effects of lorazepam on short latency afferent inhibition and short latency intracortical inhibition in humans, J Physiol564, 661–8.
79.
Di LazzaroV, PilatoF, DileoneM, ProficeP, RanieriF, RicciV, BriaP, TonaliPA, ZiemannU (2007) Segregating two inhibitory circuits in human motor cortex at the level of GABAA receptor subtypes: A TMS study, Clin Neurophysiol118, 2207–14.
80.
AlleH, HeideggerT, KrivánekováL, ZiemannU (2009) Interactions between short-interval intracortical inhibition and short-latency afferent inhibition in human motor cortex, J Physiol587, 5163–5176.
81.
MartoranaA, Di LorenzoF, ManentiG, SempriniR, KochG (2014) Homotaurine induces measurable changes of short latency afferent inhibition in a group of mild cognitive impairment individuals, Front Aging Neurosci6, 371.
82.
SunY, WuS, BuG, OnifadeMK, PatelSN, LaDuMJ, FaganAM, HoltzmanDM (1998) Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: Astrocyte-specific expression and differing biological effects of astrocyte- secreted apoE3 and apoE4 lipoproteins, J Neurosci18, 3261–3272.
